Drug Profile
Emicizumab - Chugai Pharmaceutical
Alternative Names: ACE 910; Anti-factor IXa anti-factor X humanized bispecific antibody; CH5534262; Emicizumab-kxwh; HEMLIBRA; Hemlibra; RG 6013; RO 5534262Latest Information Update: 18 Jan 2024
Price :
$50
*
At a glance
- Originator Chugai Pharmaceutical
- Developer Chugai Pharmaceutical; Emory University; Genentech; JW Pharmaceutical; Roche
- Class Antihaemorrhagics; Bispecific antibodies; Recombinant proteins
- Mechanism of Action Factor IXa stimulants; Factor X stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Haemophilia A
Most Recent Events
- 05 Jan 2024 Emory University and Genentech withdraws phase III trial for Haemophilia A (Treatment-naive, In adolescents, In adults, In children) in USA (IV) prior to enrollment due to slow enrollment and study site startup (NCT04030052)
- 09 Dec 2023 Efficacy, adverse events and pharmacokinetics data from the phase III HAVEN 7 trial in Hemophilia A presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)
- 09 Dec 2023 Pharmacodynamics data from the phase III HAVEN 7 trial in Hemophilia A presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)